FDA Sticks To Its Guns On Biosimilar Naming

 
• By David Wallace
  
Crowd
The US Has Doubled Down On Biosimilar Naming Conventions That Set It Apart From The Crowd • Source: Shutterstock

More from Regulation

More from Policy & Regulation